Search results
VTYX IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc....
WKBN 27 Youngstown· 4 days agoWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents ...
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
Zacks via Yahoo Finance· 6 days agoRinvoq is already approved to treat several autoimmune diseases like rheumatoid arthritis, psoriatic...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 2 days agoOctober 2023, the FDA approved Cosentyx for treating moderate-to-severe hidradenitis suppurativa...
Warner Financial Inc. Purchases 3,315 Shares of Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 4 days agoWarner Financial Inc. increased its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 87.9% during the fourth quarter, according to the company in its most recent 13F filing with the ...
YHB Investment Advisors Inc. Trims Stake in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 6 days agoYHB Investment Advisors Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 6.7% during the 4th quarter, according to its most recent 13F filing with the Securities ...
Johnson & Johnson (NYSE:JNJ) Issues FY24 Earnings Guidance
ETF DAILY NEWS· 6 days agoJohnson & Johnson (NYSE:JNJ – Get Free Report) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of $10.57-10.72 for the period, compared to the consensus EPS ...
Johnson & Johnson (NYSE:JNJ) Releases FY 2024 Earnings Guidance
ETF DAILY NEWS· 6 days agoJohnson & Johnson (NYSE:JNJ – Get Free Report) updated its FY 2024 earnings guidance on Tuesday. The company issued revenue guidance of $88.0 billion-$88.4 billion, compared to the consensus ...
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant...
NBC 17 Raleigh· 7 days ago− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen ...
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 8 hours agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Zacks via Yahoo Finance· 6 days agoIn October 2023, the FDA approved the drug for treating moderate to severe hidradenitis suppurativa...